Conversation 179: Medadvisor says business is well undervalued.

Written By Phil Carey

About MedAdvisor: MedAdvisor is a world-class medication management platform that empowers users to more simply manage their medication and improve adherence. MedAdvisor’s highly automated and intuitive software system connects users to tools and education materials from their local/preferred pharmacy. In the US, MedAdvisor can reach 1 in 2 Americans for opt-out health programs via ~25,000 pharmacies. In Australia, MedAdvisor has connected over 1.8 million users through more than 60% of Australian pharmacies. MedAdvisor has recently partnered with HMS in the US, Zuellig Pharma in Asia and launched into the UK on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100. Visit: mymedadvisor.com/investors

SCROLL PAST THE VIDEO BELOW

FOR A MOBILE OPTIMISED VERSION


 

CHAPTER MARKERS NOT AVAILABLE ON BELOW MOBILE VERSION

 
 
Phil Carey https://www.cornerstonemedia.com.au
Previous

Conversation 183: A look at the fundamentals of USCOM - [ASX:UCM] an Australian medical device company - to see if claims of it being grossly undervalued stack up.
Next

Conversation 175: Forget tea leaf reading - the real money is in plate reading.